Mats Johnson
About our researcher Mats Johnson
About Mats Johnson
Mats Johnson, MD, PhD, is University hospital head clinician at the Child Neuropsychiatry Centre, Sahlgrenska University Hospital, Gothenburg, and Associate Professor in Child and Adolescent Psychiatry at the Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University. He is an author of more than 50 peer-reviewed articles and conference posters, with more than 3600 citations as of April 2024.
Research interests
Mats Johnson’s main research interest has been treatments of ADHD, and he was Principal Investigator/Investigator and National Coordinator in 10 international multicenter randomized placebo-controlled trials (RCTs) of ADHD medication. He led two Swedish RCTs in Omega 3/6 treatment of ADHD and for reading ability. In recent years he led an RCT of a problem-solving programme for children with ESSENCE (PR-ESSENCE) and a 2-year open trial of medication for children with ADHD and complex comorbidities, including autism. Most recently, he and the project team at the Gillberg Neuropsychiatry Centre, are studying Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), a post-infectious illness of suspected immunologic origins, including an open long-term trial with Intravenous Immunoglobulin (IVIG) treatment. He also leads an ongoing trial of PR-ESSENCE treatment for youth with behavior problems in youth institutions in western Sweden.
Funding
Mats has received the following funding for his research
- WM Lundgrens Research Fund
- Petter Silfverskiölds Minnesfond
- Thurings Stiftelse
- Drottning Silvias Barn- och ungdomssjukhus forskningsfond
- Equazen
- Vifor Pharma
- Shire/Takeda Pharmaceuticals
- Carl Bennet AB
- Familjen Kamprads Stiftelse
- Hjärnfonden
- Octapharma
